China Prepares Site For First-In-Human Studies But Safety Concerns Remain
This article was originally published in PharmAsia News
Multinational companies have long urged China to allow first-in-human studies for innovative drugs developed outside the country. Now that wish could be getting close to reality.
You may also be interested in...
A regulatory pathway set up in China post-SARS is under stress test in the latest coronavirus outbreak, while emergency measures adopted by the country's regulator mean it’s much less burdensome to obtain approvals than before.
In a drastic move, China sends top physicians from around the country to Wuhan, finally allows a WHO expert delegation to visit hospitals in the outbreak's epicenter and welcomes foreign experts.